Bisindolylmaleimide V
| Code | Size | Price |
|---|
| AG-CR1-0023-M001 | 1 mg | £60.00 |
Quantity:
| AG-CR1-0023-M005 | 5 mg | £160.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Ro 31-6045; BIM V
Appearance:
Red crystalline solid.
CAS:
113963-68-1
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C21H15N3O2/c1-24-20(25)18(14-10-22-16-8-4-2-6-12(14)16)19(21(24)26)15-11-23-17-9-5-3-7-13(15)17/h2-11,22-23H,1H3
InChiKey:
SWAWYMIKGOHZMR-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 113963-68-1. Formula: C21H15N3O2. MW: 341.4. Negative control for protein kinase C (PKC) inhibitors. S6K inhibitor. Necrosis inhibitor.
MDL:
MFCD00236433
Molecular Formula:
C21H15N3O2
Molecular Weight:
341.4
Package Type:
Vial
Product Description:
Negative control for protein kinase C (PKC) inhibitors [1, 2]. S6K inhibitor [3]. Necrosis inhibitor [4].
Purity:
>98% (NMR)
SMILES:
CN1C(=O)C(C2=CNC3=CC=CC=C23)=C(C1=O)C1=CNC2=C1C=CC=C2
Solubility Chemicals:
Soluble in DMSO or methanol.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides: P.D. Davis, et al.; J. Med. Chem. 35, 177 (1992) | The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C: D. Toullec, et al.; J. Biol. Chem. 266, 15771 (1991) | Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70(s6k)/p85(s6k): implications for the analysis of S6K signalling: N. Marmy-Conus, et al.; FEBS Lett. 519, 135 (2002) | Bisindolylmaleimide I and V inhibit necrosis induced by oxidative stress in a variety of cells including neurons: R. Asakai, et al.; Neurosci. Res. 44, 297 (2002)
Related Products
| Product Name | Product Code | Supplier | Bisindolylmaleimide I . Hydrochloride | AG-CR1-0110 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|